Literature DB >> 20484027

CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer.

Matthew J Meyer1, Jodie M Fleming, Amy F Lin, S Amal Hussnain, Erika Ginsburg, Barbara K Vonderhaar.   

Abstract

Defining the populations of tumor-initating cells that are present in tumors is a first step in developing therapeutics to target these cells. We show here that both CD44(pos)CD24(neg) and CD44(pos)CD24(pos) cell populations in estrogen receptor (ER) alpha-negative breast tumors are tumorigenic in murine xenograft models. We also describe a third population of xenograft-initiating cells (XIC) enriched in CD44(pos)CD49f(hi)CD133/2(hi) cells that display heightened tumorigenicity, self-renewal in vivo, and the capacity to give rise to functional and molecular heterogeneity. Consistent with their capacity for self-renewal, these cells express elevated levels of Sox2, Bmi-1, and/or Nanog and their CpG islands are hypermethylated relative to nontumorigenic cells. These differences in methylome regulation may be responsible for the dramatic functional differences between the two populations. The identification of CD44(pos)CD49f(hi)CD133/2(hi) XIC in ER-negative tumors may lead to expanded understanding of these tumors and ultimately the development of therapeutics designed to specifically target the cells. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484027      PMCID: PMC4129519          DOI: 10.1158/0008-5472.CAN-09-3619

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Cell type-specific DNA methylation patterns in the human breast.

Authors:  Noga Bloushtain-Qimron; Jun Yao; Eric L Snyder; Michail Shipitsin; Lauren L Campbell; Sendurai A Mani; Min Hu; Haiyan Chen; Vadim Ustyansky; Jessica E Antosiewicz; Pedram Argani; Marc K Halushka; James A Thomson; Paul Pharoah; Angel Porgador; Saraswati Sukumar; Ramon Parsons; Andrea L Richardson; Martha R Stampfer; Rebecca S Gelman; Tatiana Nikolskaya; Yuri Nikolsky; Kornelia Polyak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

2.  CD44 is of functional importance for colorectal cancer stem cells.

Authors:  Lei Du; Hongyi Wang; Leya He; Jingyu Zhang; Biyun Ni; Xiaohui Wang; Haijing Jin; Nathalie Cahuzac; Maryam Mehrpour; Youyong Lu; Quan Chen
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 3.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Rev Cancer       Date:  2008-09-11       Impact factor: 60.716

4.  Genome-scale DNA methylation maps of pluripotent and differentiated cells.

Authors:  Alexander Meissner; Tarjei S Mikkelsen; Hongcang Gu; Marius Wernig; Jacob Hanna; Andrey Sivachenko; Xiaolan Zhang; Bradley E Bernstein; Chad Nusbaum; David B Jaffe; Andreas Gnirke; Rudolf Jaenisch; Eric S Lander
Journal:  Nature       Date:  2008-07-06       Impact factor: 49.962

5.  CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.

Authors:  Venkateswaran Subramaniam; Isabella R Vincent; Helena Gardner; Emily Chan; Helena Dhamko; Serge Jothy
Journal:  Exp Mol Pathol       Date:  2007-05-13       Impact factor: 3.362

6.  Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.

Authors:  Samuel Godar; Tan A Ince; George W Bell; David Feldser; Joana Liu Donaher; Jonas Bergh; Anne Liu; Kevin Miu; Randolph S Watnick; Ferenc Reinhardt; Sandra S McAllister; Tyler Jacks; Robert A Weinberg
Journal:  Cell       Date:  2008-07-11       Impact factor: 41.582

7.  Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy.

Authors:  Venkateswaran Subramaniam; Isabella Regina Vincent; Maliheh Gilakjan; Serge Jothy
Journal:  Exp Mol Pathol       Date:  2007-09-07       Impact factor: 3.362

8.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Authors:  Sven Rottenberg; Janneke E Jaspers; Ariena Kersbergen; Eline van der Burg; Anders O H Nygren; Serge A L Zander; Patrick W B Derksen; Michiel de Bruin; John Zevenhoven; Alan Lau; Robert Boulter; Aaron Cranston; Mark J O'Connor; Niall M B Martin; Piet Borst; Jos Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

9.  Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal.

Authors:  Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Shanté Williams; Akihiro Otsuki; Gerard Nuovo; Abhik Raychaudhury; Herbert B Newton; E Antonio Chiocca; Sean Lawler
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

10.  Efficient tumour formation by single human melanoma cells.

Authors:  Elsa Quintana; Mark Shackleton; Michael S Sabel; Douglas R Fullen; Timothy M Johnson; Sean J Morrison
Journal:  Nature       Date:  2008-12-04       Impact factor: 49.962

View more
  80 in total

Review 1.  Identifying and targeting tumor-initiating cells in the treatment of breast cancer.

Authors:  Wei Wei; Michael T Lewis
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

Review 2.  Pancreatic cancer stem cells.

Authors:  Ya-Yun Zhu; Zhou Yuan
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Regulated splicing of the α6 integrin cytoplasmic domain determines the fate of breast cancer stem cells.

Authors:  Hira Lal Goel; Tatiana Gritsko; Bryan Pursell; Cheng Chang; Leonard D Shultz; Dale L Greiner; Jens Henrik Norum; Rune Toftgard; Leslie M Shaw; Arthur M Mercurio
Journal:  Cell Rep       Date:  2014-04-24       Impact factor: 9.423

4.  Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.

Authors:  Javier A Menendez; Tomás Alarcón; Bruna Corominas-Faja; Elisabet Cuyàs; Eugeni López-Bonet; Angel G Martin; Luciano Vellon
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

5.  Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.

Authors:  Justin D Lathia; Ofer Reizes; Praveena S Thiagarajan; Masahiro Hitomi; James S Hale; Alvaro G Alvarado; Balint Otvos; Maksim Sinyuk; Kevin Stoltz; Andrew Wiechert; Erin Mulkearns-Hubert; Awad Jarrar; Qiao Zheng; Dustin Thomas; Thomas Egelhoff; Jeremy N Rich; Huiping Liu
Journal:  Stem Cells       Date:  2015-05-15       Impact factor: 6.277

Review 6.  Breast cancer stem cells-from origins to targeted therapy.

Authors:  Woei Chyi Sin; Chooi Ling Lim
Journal:  Stem Cell Investig       Date:  2017-11-29

7.  Immunotoxin targeting CD133(+) breast carcinoma cells.

Authors:  John R Ohlfest; David M Zellmer; Jayanth Panyam; Suresh Kumar Swaminathan; Seunguk Oh; Nate N Waldron; Shoko Toma; Daniel A Vallera
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

Review 8.  Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?

Authors:  Hidetaka Shima; Akimitsu Yamada; Takashi Ishikawa; Itaru Endo
Journal:  Gland Surg       Date:  2017-02

9.  Identification, functional characterization, and pathobiological significance of GLI1 isoforms in human cancers.

Authors:  Richard L Carpenter; Hui-Wen Lo
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

10.  Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model.

Authors:  Elizabeth M Peek; David R Li; Hanwei Zhang; Hyun Pyo Kim; Baohui Zhang; Isla P Garraway; Arnold I Chin
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.